The Leading Global Cause of Death
Cardiovascular disease (CVD) is the leading cause of death globally, accounting for 25% of deaths in the U.S. and 31% of deaths worldwide. Nearly 18 million people die each year from CVD-related events including heart attack and stroke.
Despite current standard of care treatment, residual risk of heart attack, stroke and death remains high in patients with CVD. Developing new treatments to reduce the residual cardiovascular risk is a challenge due to the heterogeneity of the patient population and the resulting variation in response to treatment.
Scientific advances in precision medicine now allow for a patient’s genetic profile to be considered during the development of new treatments in order to address the complexity of CVD and the heterogeneity of this patient population. This targeted approach identifies individual patients based on a specific genetic subtype, who may benefit from a particular treatment.
DalCor is developing dalcetrapib, a CETP inhibitor, as a precision medicine to reduce cardiovascular risk above and beyond the current standard of care in patients who carry the ADCY9 rs1967309 AA specific genotype.